TransCode Therapeutics Inc (RNAZ) Share Price

Will be sub-dollar and then soon another Reverse Split will be proposed again by this shady CEO and call it again "In the Best interests of the shareholders "....

Looking better $6s just about.18 cents add a few. Market cap collapsing

RNAZ, new 52=week low

Great job dudes!! Management 8M Year end bonus for christmas, Job well done

Nobel prize and all the scientific community didn’t even acknowledge the existence of this nobel prize clinical scam

It was a planned sabotage from the start, Master Dudley screwed all shareholders and passed the torch to the biggest scumbag rat CFO cook the books fill up his pockets Fitzgerald

$150,000 a share IPO in 2022 to record low $6.75 congrats to all longs congrats to all of management

Micro rna nobel scientific broke community is the scam of the century

Management all going to jail for fraud

Where are you hiding you dirty rat cunt CSO Zdravka Medarova, you disappeared and fucked in vestors all your career you dirty whore

Buy some shares on the open market you broke bitch dirty cunt Zdravka Medarova you love to screw investors and fill up your Louis Vuitton purse while you fuck all your shareholders up the ass you dirty whore crack head bitch

The cunt scam artist of the scientific community Zdravka Medarova, chief Scientific Officer & Founder of transscam is going to jail for fraudulent activities in bed with the shorts like a cheap crack head whore, burn in hell where you belong cunt for sabotaging the only hope for terminally ill cancer patients

Put them all on the electric chair for sabotaging the only hope for terminally ill cancer patients,No kidding the rat bastard CEO Fitzgerald and all the lab rat bastards in management including founders love to screw their investors since inception a planned out sabotage to pocket all investors money while they short their shareholders dry, Burn In hell motherfuckers

Shorts in bed with management are in big trouble for robbing investors blind
https://franknez.com/short-sellers-are-now-under-federal-investigation-for-collusion/

Get on CNN Fitzgerald and founder scam artists, show the world what you got instead of scam media
https://www.proactiveinvestors.com/companies/news/1057060/transcode-therapeutics-begins-dosing-patients-in-phase-1-trial-for-metastatic-cancer-therapy-1057060.html?region=ca®ion=ca

Yo’ Tommy Boy you must be happy 8M Coming your way into your pocket while you fuxk investors with your shorts friends

Get to work on Cnn spread the news your a scam artist Tommy boy Fitzerald ,after all the money and shares you robbed this company and its shareholders do something usefull for the first time in your career burnout,

What happened to 7th RNA Targeted Drug Discovery & Development Summit InBoston? TTX scam missing in action? Accelerating Safe & Potent RNA-Targeting Small Molecules Towards the Clinic??
all i see is a real company Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.

The scam artist founders of TransCode Therapeutics nobel prize hoax of the scientific community are Robert Michael Dudley, Zdravka Medarova, and Anna Moore:
Robert Michael Dudley: Co-founder and former CEO of TransCode Therapeutics
Zdravka Medarova: Co-founder and Chief Scientific Officer of TransCode Therapeutics
Anna Moore: Co-founder and Scientific Advisor of TransCode Therapeutics
Other key executives at TransCode Therapeutics include:i’m

Wash Rinse Repeat scam artists of the nobel prize micro rna peasants

TransCode’s Chief Technology Officer and co-founder, Dr. Zdravka Medarova, said, “Demonstrating the feasibility of delivering TTX-MC138 to malignant lesions in humans could unlock the potential of a wide array of RNA-targeted therapeutics, since the TTX platform permits a modular drug design, centered around the same delivery vehicle but with different payloads in terms of the sequence, design, and mechanism of action of the nucleic acid being delivered.”

The Phase 0 clinical trial will be conducted under an exploratory Investigational New Drug (eIND) application. In TransCode’s planned clinical trial, up to 12 patients will be given a single microdose of radiolabeled TTX-MC138 followed by noninvasive positron emission tomography-magnetic resonance imaging (PET-MRI). The trial is intended to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions and the pharmacokinetics of the therapeutic candidate at a subtherapeutic dose in cancer patients. The trial could yield critical data regarding future therapeutic dose levels, dose schedule, and potential safety that could inform later stage clinical trials. This trial is not intended to demonstrate therapeutic effect.


“We are pleased that the FDA and IRB have completed their reviews of the Phase 0 clinical trial application and authorized commencement of the trial,” said Susan Duggan, TransCode’s Senior Vice President of Operations. “The FDA authorization and IRB approval to initiate this trial mark the development of TransCode Therapeutics into a clinical-stage oncology company.

It’s been 18 months we still waiting for results Management lied for to long so they can rob investor blind these nobel prize scam artist of the scientific community

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 27 2023 - 7:00AM

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate delivery of TransCode’s lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors. ?TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could become a treatment for many of these cancers.
“We are very pleased to have received IRB Approval for our FIH clinical trial,” said TransCode’s Chief Executive Officer and co-founder, Michael Dudley. “We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate to metastatic lesions in patients with advanced solid tumors. The delivery of RNA therapeutics to sites other than the liver has remained a significant challenge for decades. Overcoming this challenge would represent an unprecedented step in unlocking therapeutic access to a variety of well documented genetic targets involved in a range of cancers and beyond.”


The Company believes that TTX-MC138 has the potential to dramatically improve clinical outcomes in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas, and others. In a preclinical murine model of triple-negative breast cancer, treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In a more aggressive murine model representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated. In a murine model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. In addition to murine models of cancer, TTX-MC138 was successfully delivered and was well tolerated in a case study of spontaneous feline mammary carcinoma.


TransCode’s Chief Technology Officer and co-founder, Dr. Zdravka Medarova, said, “Demonstrating the feasibility of delivering TTX-MC138 to malignant lesions in humans could unlock the potential of a wide array of RNA-targeted therapeutics, since the TTX platform permits a modular drug design, centered around the same delivery vehicle but with different payloads in terms of the sequence, design, and mechanism of action of the nucleic acid being delivered.”

The Phase 0 clinical trial will be conducted under an exploratory Investigational New Drug (eIND) application. In TransCode’s planned clinical trial, up to 12 patients will be given a single microdose of radiolabeled TTX-MC138 followed by noninvasive positron emission tomography-magnetic resonance imaging (PET-MRI). The trial is intended to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions and the pharmacokinetics of the therapeutic candidate at a subtherapeutic dose in cancer patients. The trial could yield critical data regarding future therapeutic dose levels, dose schedule, and potential safety that could inform later stage clinical trials. This trial is not intended to demonstrate therapeutic effect.


“We are pleased that the FDA and IRB have completed their reviews of the Phase 0 clinical trial application and authorized commencement of the trial,” said Susan Duggan, TransCode’s Senior Vice President of Operations. “The FDA authorization and IRB approval to initiate this trial mark the development of TransCode Therapeutics into a clinical-stage oncology company.

This is what real rna companies do scammers, shame on you
Lilly Opens $700M R&D Center in Boston for Genetic Medicines
https://www.biospace.com/business/lilly-opens-700m-r-d-center-in-boston-for-genetic-medicines
The new Lilly Seaport Innovation Center in Boston
Lilly’s newly opened Seaport Center in BostonCourtesy of Eli Lilly and Company
Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.

Eli Lilly on Tuesday debuted in America’s biggest biotech hub—Boston—with a new facility dedicated to the research and development of cutting-edge genetic therapies.

Dubbed the Lilly Seaport Innovation Center (LSC), the new site will expand the pharma’s U.S. footprint by 346,000 square feet and will be able to house 500 scientists and researchers. The LSC can also accommodate 200 staff from within the innovation hub Lilly Gateway Labs, which the pharma uses to connect earlier stage biotechs with its platforms and expertise.

The LSC will work on advancing RNA- and DNA-based therapies while also allotting some its resources to discovering new drug targets for Lilly’s priority disease areas, such as diabetes, obesity and cardiovascular diseases. The pharma will also leverage the LSC for R&D in neurodegeneration and chronic pain.

Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories, in a statement said that the opening of the LSC will allow the pharma to collaborate “with leading institutions and new talent to continue delivering transformative medicines for the people who need them the most.”

With the LSC’s opening, Lilly brings the obesity competition closer to its chief rival Novo Nordisk, which in February 2024 opened an R&D site in the Boston area, according to the Boston Business Journal. The pharma first announced this expansion in March 2023, revealing at the time that the site will similarly focus on genetic therapies.

Lilly has steadily been gaining ground on Novo in the weight-loss drug race. In the second quarter of 2024, Lilly’s product sales impressed investors by easily beating consensus forecasts. Meanwhile, investors found Novo’s performance disappointing in Q2, with its shares dropping more than 7% shortly after the pharma released its earnings report.

Supply headwinds can partly account for this disparity, with Lilly clearing up the U.S. shortages for all doses of type 2 diabetes medication Mounjaro and weight-loss drug Zepbound. By contrast, while Novo has made progress on stabilizing its supply, one dose of Wegovy still has limited availability.

On the efficacy front, Lilly appears to have Novo beat as well. Last month, a study published in JAMA Internal Medicine found that Mounjaro could elicit 2.4% greater weight-loss than Novo’s Ozempic—and this gap widened even further through six and 12 months of treatment.

The rivals are continuing to compare their incretin therapies against each other. Lilly is currently conducting the Phase IIIb SURMOUNT-5 head-to-head study in overweight or obese adults without type 2 diabetes. Results from this trial are expected in November 2024. Meanwhile, Novo is looking to challenge Zepbound with its next-generation therapy CagriSema with a Phase III study that is expected to wrap up in the second half of 2025.

Hit the crack pipe Fitzgerald this is how you screw Wall Street
https://www.proactiveinvestors.ca/companies/news/1057060/transcode-therapeutics-begins-dosing-patients-in-phase-1-trial-for-metastatic-cancer-therapy-1057060.html?region=ca

Buy shares of your company you rat bastards instead of robbing then from your shareholders motherfuckers
The founders of TransCode Therapeutics are Robert Michael Dudley, Zdravka Medarova, and Anna Moore:
Robert Michael Dudley: Co-founder and former CEO of TransCode Therapeutics
Zdravka Medarova: Co-founder and Chief Scientific Officer of TransCode Therapeutics
Anna Moore: Co-founder and Scientific Advisor of TransCode Therapeutics
Other key executives at TransCode Therapeutics include:
Dr. Daniel R. Vlock M.D.: Chief Medical Officer
Ms. Susan Duggan M.B.A., R.N.: Senior Vice President of Operations
Tom Fitzgerald: Interim CEO and CFO
Subrata Ghosh, PhD: Principal Scientist
Neil Robertson, PhD: Senior Scientist
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board
TransCode Therapeutics is headquartered in Newton, MA

The word is out on wallstreet.These dirty rats in the scientific Nobel community screwed investors all their careers since inception with consulting fees in their pockets

The founders of TransCode Therapeutics are Robert Michael Dudley, Zdravka Medarova, and Anna Moore:
Robert Michael Dudley: Co-founder and former CEO of TransCode Therapeutics
Zdravka Medarova: Co-founder and Chief Scientific Officer of TransCode Therapeutics
Anna Moore: Co-founder and Scientific Advisor of TransCode Therapeutics
Other key executives at TransCode Therapeutics include:
Dr. Daniel R. Vlock M.D.: Chief Medical Officer
Ms. Susan Duggan M.B.A., R.N.: Senior Vice President of Operations
Tom Fitzgerald: Interim CEO and CFO
Subrata Ghosh, PhD: Principal Scientist
Neil Robertson, PhD: Senior Scientist
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board
TransCode Therapeutics is headquartered in Newton, MA all

Buy some shares CEO Fitzgerald you dirty rat bastard and the rest of the lab rats in management founders CSO cunt of the Nobel scientific community
Insider buying is the legal practice of corporate insiders—such as executives, directors, or significant shareholders—buying shares of their company's stock on the open market. Investors and market analysts closely monitor this activity since it might offer insights into a company's prospects

This proves the nobel prize scientific community has no credibility, They are all broke birdbrains from the lab ready to screw wallstreet

Let the insiders in management fraud artists of the scientific nobel broke community buy on the open market if they believe in their own shit show bullshit scams trials They shit on all us for too long now

Rot In hell CSO Zdravka Medarova for sabotaging the only hope for terminally ill cancer patients while you fill up your Louis Vuitton purse and screw investors all your career you dirty cunt

Where's the clinical news founder cunt Zdravka Medarova CSO, 8 million going to go fast in your Louis Vuitton purse while you fuck all of retail

The rat bastards in management love to screw their shareholders, They act as if they are victims, while the cunt Zdravka Medarova CSO in bed with the shorts fucking all investors while filling up her Louis Vuitton purse

Live the dream You can do it Zdravka Medarova, PhD Chief Scientific Officer & Founder of the scientific nobel prize scam machine designed to funnel money in her pockets while shareholders get rapped and fucked since inception

Form D 8Million- Let these nobel prize broke scientific community criminals buy on the open market if they truly believe in this piece of shit they call a company

Congratulations to all the siphoning founders of transcode therapeutics con artists of the scientific nobel community , They all have a bright future in a federal prison

Rnaz $cam artist$$ approved$$$

Floor price is out $weet$$ $2.89

That bastard rat scam artist founder Robert Michael Dudley passed the torch to the rat bastard Tom Fitzgerald to fuck investors up the ass while they all funnel the cash cow in their pockets and fuck all shareholders while the whore CSO cunt is in bed with the shorts

Zdravka Medarova, PhD Chief Scientific Officer & Founding cunt of transcode therapeutics,with Robert Michael Dudley scam artist of the century fucked investors all their careers and are the scam artists of the scientific community Nobel prize Micro RNA clinical trials burn in hell motherfuckers
https://informaconnect.com/rna-leaders-usa/speakers/zdravka-medarova/

That's cause the bastard rat scumbag CEO Fitzgerald and the founding cunt Zdravka Medarova, PhD Chief Scientific Officer of the micro RNA Nobel prize fucked everyone up the ass all their careers They pocketed over 50m since inception and legally robbed shareholders all their miserable careers as fraud as
Artists of the scientific community

PPS now at .218, pre-split...

Let that dirty cunt founder Zdravka Medarova, PhD Chief Scientific Officer buy on the open market if that cunt believes in herself, That bitch fucked investors since inception and slept like a whore in bed with the shorts so she can fuck all of retail and shareholder while she fills up her Louis Vuitton purse. Wake up bitch you fucked everyone with your Nobel prize scam

Go Fitzgerald Go burn all your shareholders with this scam empty shell company motherfucker, Everyone knows your a scam artists with the founder CSO cunt disgrace of the scientific Nobel prize community

CSO & Founder is a disgrace to the scientific RNA community, The cunt screwed investors all her career while sleeps with the short bastards of the earth while she fills up her Louis Vuitton purse

Pull the plug CEO rat bastard Fitzgerald in Boston Gala

That’s the spirit dudes!!! Let them have it

Burn this empty shell scam machine to the ground in hell where you belong CEO Fitzgerald founder CSO cunt bitch you dirty rat bastard motherfuckers

That’s what scam artists do for a living, i’m glad management have been exposed to the public eyes for their fraudulent activities in bed with the shorts to destroy shareholders equity

This share price will continue to bleed lower unless some frantic results are announced which I do not see happening at this time. So in my opinion, they will continue to sell shares again and then when subdollar occurs will announce another bogus "meeting" and then supposed approval of another reverse split. Simply disgusting that management is allowed to get away with these shady tactics in my opinion since we did not see any actual vote count since the meeting was without video where you can see them speaking. Facial expressions says a lot about someone and they did not show their faces!

Management are still painting short fake walls so they can collapse this piece of garbage and strategically R/S next week

The rat bastards in management know they got busted for fraudulent activities and are now hiding in their rat holes